Truist raised the firm's price target on AdvanSix to $20 from $19 and keeps a Hold rating on the shares. Input cost inflation is in the near term overshadowing the benefits of a relatively favorable growth outlook for the Plant Nutrients business, the analyst tells investors in a research note. AdvanSix is undergoing efforts to rationalize costs and capital spending, which should support positive free cash flow generation in 2026 despite what the firm expects to be meaningful y/y EBITDA pressure, Truist adds.
